Laudisio et al., 2018 - Google Patents
Obesity and breast cancer in premenopausal women: Current evidence and future perspectivesLaudisio et al., 2018
View PDF- Document ID
- 2197660972856239896
- Author
- Laudisio D
- Muscogiuri G
- Barrea L
- Savastano S
- Colao A
- Publication year
- Publication venue
- European Journal of Obstetrics & Gynecology and Reproductive Biology
External Links
Snippet
There is raising evidence reporting an increased incidence of breast cancer over the past decades. Every year approximately 1.4 million new cases of breast cancer are diagnosed worldwide, with a mortality rate of approximately 450,000/year. Out of these cases, 6.6% are …
- 206010006187 Breast cancer 0 title abstract description 121
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laudisio et al. | Obesity and breast cancer in premenopausal women: Current evidence and future perspectives | |
| Mili et al. | Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations | |
| Schmidt et al. | The integrative role of leptin, oestrogen and the insulin family in obesity‐associated breast cancer: potential effects of exercise | |
| Oliveira et al. | The role of sarcopenia in the risk of osteoporotic hip fracture | |
| Cardoso et al. | The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer | |
| Friedenreich et al. | Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects | |
| Østergren et al. | Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial | |
| Fentiman | The endocrinology of male breast cancer | |
| Yun et al. | Effect of cross-sex hormones on body composition, bone mineral density, and muscle strength in trans women | |
| Choudhary et al. | The effect of raloxifene on serum prolactin level in patients with prolactinoma | |
| Abe et al. | Metabolic syndrome and its components in adult hypopituitary patients | |
| Duarte et al. | Estrogens and selective estrogen receptor modulators in acromegaly | |
| Sehl et al. | Potential mechanisms of age acceleration caused by estrogen deprivation: do endocrine therapies carry the same risks? | |
| Srinivasan et al. | A systematic review: Does insulin resistance affect the risk and survival outcome of breast cancer in women? | |
| Osataphan et al. | Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations | |
| Jain et al. | Male breast cancer | |
| Farooki | NCCN bone health task force: key recommendations | |
| Pyra et al. | Puberty: normal, delayed, and precocious | |
| Ganz | Pituitary adenomas | |
| Gupta et al. | Goserelin ovarian ablation failure in premenopausal women with breast cancer | |
| Gomez et al. | Determinants of sex hormone-binding globulin concentrations in a cross-sectional study of healthy men randomly selected | |
| Sun et al. | Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: a systematic review and meta-analysis of randomized controlled trials | |
| Chiechi et al. | Factors of risk for breast cancer influencing post-menopausal long-term hormone replacement therapy | |
| Poltronieri et al. | Changes in Body Adiposity in Women Undergoing Breast Cancer Treatment: A Scoping Review | |
| Gamboa et al. | Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case |